top of page

Share Data

At Anavex Life Sciences, we strive to produce sustained strong performance and shareholder value.

NASDAQ: AVXL

Key Data

Industry

Biopharmaceutical

Sector

New drug discovery

Fiscal year end

September 30

Shares issued and outstanding

 82,112,511*

Stock purchase warrants

160,000 **

Stock options

14,109,363**

Fully diluted

 96,355,874**

Cash

$143.8 million

Debt

Nil **

Trading symbol

AVXL

52-week range

$4.87 - $10.45

Financial statements and filings

Anavex's filings can be found on EDGAR

Investor relations

Transfer agent

Nevada Agency and Trust

 

50 West Liberty Street,

Suite 880

Reno, Nevada 89501

Tel:  (775) 322-0626

Fax: (775) 322-5623

email: info@natco.org

Resident Agent

email: corpserve@natco.org

Website: www.natco.org

*   As of Febuary 7, 2024

** As of December 31,  2023

Forms - Reverse Stock Split

Internal Revenue Service (United States) - Form 8937

bottom of page